Brandenburg Kapital - News about SphingoTec GmbH
Boditech Med has entered into a license agreement with SphingoTec
Hennigsdorf – November 2022. Boditech Med Inc., a globally leading diagnostics company from Korea,announced its first global licensing agreement with SphingoTec for its highly innovative kidney function marker penKid.
Under the terms of this agreement, Boditech Med has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma™ Point of Care platforms. SphingoTec has a developed penKid, a unique biomarker for real-time assessment of kidney functionproviding physicians at the ED and ICU with urgently needed information on kidney function. Through this partnership, Boditech and SphingoTec will make the biomarker penKid available on Boditech Med's worldwide installed base with the goal of improving the management of patients suffering from acute kidney injury (AKI).
SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized medicine in intensive care. The biomarkers provide important, organ-specific information for monitoring acute disease progressions such as sepsis or acute renal failure. In doing so, they support clinical decisions with the aim of improving patient management.
Brandenburg Kapital GmbH has been supporting the company since 2018.
Read the full press release here:
For more information, please visit: www.brandenburg-kapital.de, www.sphingotec.com